tiprankstipranks
Advertisement
Advertisement

NGEN Stock Latest News

NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
Company AnnouncementsNervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
2d ago
6K
NGEN
NervGen Pharma 24M share Spot Secondary priced at $2.50
PremiumThe Fly
NervGen Pharma 24M share Spot Secondary priced at $2.50
2d ago
NGEN
NervGen Pharma secondary being re-offered at $2.50 per share
PremiumThe Fly
NervGen Pharma secondary being re-offered at $2.50 per share
3d ago
NGEN
NervGen Pharma announces common share offering, no amount given
PremiumThe Fly
NervGen Pharma announces common share offering, no amount given
3d ago
NGEN
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
PremiumCompany Announcements
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
6d ago
6K
NGEN
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
PremiumThe FlyNervGen Pharma reports Q1 EPS (2c), consensus (7c)
6d ago
NGEN
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
Premium
Company Announcements
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
9d ago
6K
NGEN
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
Premium
Company Announcements
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
27d ago
6K
NGEN
NervGen Pharma appoints Keith Vendola as CFO
PremiumThe Fly
NervGen Pharma appoints Keith Vendola as CFO
27d ago
NGEN
NervGen Pharma initiated with a Buy at H.C. Wainwright
PremiumThe Fly
NervGen Pharma initiated with a Buy at H.C. Wainwright
27d ago
NGEN
NervGen Pharma initiated with a Buy at Lucid Capital
PremiumThe Fly
NervGen Pharma initiated with a Buy at Lucid Capital
1M ago
NGEN
NervGen Pharma price target raised to $12 from $10 at Maxim
PremiumThe Fly
NervGen Pharma price target raised to $12 from $10 at Maxim
2M ago
NGEN
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
PremiumCompany AnnouncementsNervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
2M ago
NGEN
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
Premium
The Fly
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
2M ago
NGEN
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
Premium
The Fly
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
2M ago
NGEN
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
PremiumRatings
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
2M ago
NGEN
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
PremiumCompany Announcements
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
2M ago
NGEN
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
PremiumCompany Announcements
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
2M ago
NGEN
NervGen Pharma to delist shares from TSX
PremiumThe Fly
NervGen Pharma to delist shares from TSX
2M ago
NGEN
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel
PremiumThe FlyNervGen Pharma price target raised to C$6.75 from C$5 at Stifel
3M ago
NGEN
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
Premium
The Fly
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
3M ago
NGEN
STOK
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
Premium
Company Announcements
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
3M ago
NGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >